Blood Flow Restriction for Optimizing Balance in Parkinson's Disease
This study is looking at how a special type of exercise called Blood Flow Restriction training (BFR) combined with balance-challenging exercises (Instability Resistance Training, or IRT) might help people with Parkinson's disease. BFR involves wearing cuffs on your arms or legs to reduce blood flow during exercise. Researchers want to see if this combination improves symptoms like balance, walking, and endurance. You might be able to join if you are between 40 and 85 years old, have Parkinson's disease (Hoehn and Yahr stage 2-4), and have a Mini-Mental State Examination score of 23 or higher. The main goal is to see if this approach is practical and well-tolerated over 6 weeks. The current status of this study is unclear.
- Study design
- This interventional study plans to enroll 20 participants. There will be two groups: one doing IRT with BFR, and another doing only IRT.
- What's involved
- Each exercise session will last about 45 minutes. The study will measure effects on walking, balance, and endurance from the start to 6 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 6 weeks to measure feasibility.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Blood Flow Restriction for Optimizing Balance in Parkinson's Disease
At a glance
Conditions
NCT06508801
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of Texas Health Science Center at San Antonio
San Antonio, Texasno site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Anjali Sivaramakrishnan, PhD, PT · PRINCIPAL_INVESTIGATOR · The University of Texas Health Science Center at San Antonio
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Feasibility metricBaseline to 6 weeks
The treatment will be considered acceptable if the dropout and significant adverse event rate is less than 20%, that is no more than 2 out of 10 participants in the treatment group either 1) drop out, 2) withdraw consent, or 3) have a significant adverse event (Grade 3 or higher on 5 point scale where 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, and 5 = death). Results will be reported as percentage of participants that dropped out.